Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $105.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 90.36% from the stock's current price. HC Wainwright also issued estimates for Praxis Precision Medicines' Q1 2026 earnings at ($4.32) EPS, Q2 2026 earnings at ($5.01) EPS, Q3 2026 earnings at ($5.02) EPS and Q4 2026 earnings at ($5.03) EPS.
A number of other research firms have also recently commented on PRAX. Wedbush upped their price objective on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a research report on Monday, May 5th. Oppenheimer boosted their price target on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Chardan Capital assumed coverage on Praxis Precision Medicines in a report on Wednesday, May 7th. They set a "buy" rating and a $80.00 price target for the company. Finally, Needham & Company LLC reissued a "buy" rating and set a $80.00 price target on shares of Praxis Precision Medicines in a report on Thursday, June 12th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $94.11.
Check Out Our Latest Stock Report on Praxis Precision Medicines
Praxis Precision Medicines Stock Up 2.4%
PRAX traded up $1.31 during trading on Friday, reaching $55.16. 587,675 shares of the company were exchanged, compared to its average volume of 371,225. The company's 50-day moving average is $43.38 and its two-hundred day moving average is $49.89. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -5.15 and a beta of 2.60. Praxis Precision Medicines has a 12-month low of $26.70 and a 12-month high of $91.83.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 50.42%. Equities analysts forecast that Praxis Precision Medicines will post -10.22 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of PRAX. GF Fund Management CO. LTD. purchased a new stake in Praxis Precision Medicines during the 4th quarter worth $30,000. Graham Capital Management L.P. purchased a new stake in Praxis Precision Medicines during the 4th quarter worth $209,000. KLP Kapitalforvaltning AS purchased a new stake in Praxis Precision Medicines during the 4th quarter worth $215,000. Envestnet Asset Management Inc. purchased a new stake in Praxis Precision Medicines during the 4th quarter worth $231,000. Finally, Freestone Grove Partners LP purchased a new stake in Praxis Precision Medicines during the 4th quarter worth $237,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.
About Praxis Precision Medicines
(
Get Free Report)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
See Also

Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.